Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Desensitization and Tachyphylaxis

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.

GPCR Desensitization

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Real-world persistence with antifibrotic treatments: a nationwide study on claims data in France (The REPEAT study).

Respiratory research·2026

Same author

Efficacy and safety of eptinezumab in adults with chronic migraine and medication-overuse headache who also received patient education: 24-week results of the randomized RESOLUTION trial.

The journal of headache and pain·2026

Same author

Benefits of eptinezumab on patient-reported disease burden and health-related quality of life in adults with chronic migraine and medication-overuse headache: Results from the placebo-controlled RESOLUTION trial.

Cephalalgia : an international journal of headache·2026

Same author

Milk Neoallergen in Orange Cheese Rinds?

Journal of investigational allergology & clinical immunology·2026

Same author

Migraine, headache disorders, and brain health: aligning advocacy with the UN Sustainable Development Goals.

The journal of headache and pain·2026

Same author

Harnessing the lung microbiome for precision management of fibrotic lung disease.

Trends in molecular medicine·2026

Same journal

Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension study.

Headache·2026

Same journal

American Headache Society 68th Annual Scientific Meeting June 4-7, 2026, Orlando, Florida.

Headache·2026

Same journal

In Memoriam-Doctor J. Keith Campbell.

Headache·2026

Same journal

Hypothalamus as a conductor of the migraine prodrome: A narrative review.

Headache·2026

Same journal

New academic year in Headache.

Headache·2026

Same journal

Essential readings in headache medicine: Top 10 educational articles from 2025.

Headache·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 8, 2026

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

First successful protocol for desensitization to eptinezumab.

Benoit Gerard¹, Hubert Praudel¹, Michel Lanteri-Minet^2,3

¹Département de pneumologie et d'oncologie thoracique, Centre Hospitalier Universitaire de Nice, IHU RespirERA, Université Côte d'Azur, Nice, France.

|December 20, 2025

Summary

This summary is machine-generated.

Hypersensitivity reactions to eptinezumab, a migraine prevention drug, were investigated. Skin tests ruled out an IgE-mediated mechanism, and a desensitization protocol proved safe and effective for patients.

Keywords:

allergy desensitization eptinezumab skin test

More Related Videos

An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation

An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation

Published on: April 27, 2021

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

Related Experiment Videos

Last Updated: Jan 8, 2026

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation

An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation

Published on: April 27, 2021

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

Area of Science:

Immunology
Neurology
Pharmacology

Background:

Eptinezumab is an anti-CGRP monoclonal antibody for migraine prevention.
Hypersensitivity reactions to eptinezumab have been observed in clinical trials.
The mechanism underlying these hypersensitivity reactions remains unclear.

Purpose of the Study:

To investigate the mechanism of hypersensitivity reactions to eptinezumab.
To determine if the hypersensitivity reactions are immunoglobulin E (IgE)-mediated.
To evaluate the safety and efficacy of a proposed desensitization protocol.

Main Methods:

Performed eptinezumab skin tests on two patients with immediate hypersensitivity reactions.
Administered a 10-step desensitization protocol to the patients.

Main Results:

Eptinezumab skin tests were negative in both patients, suggesting a non-IgE-mediated mechanism.
Both patients successfully completed the 10-step desensitization protocol.

Conclusions:

The hypersensitivity reactions to eptinezumab are likely not IgE-mediated.
The hospital-based 10-step desensitization protocol is safe and effective for managing eptinezumab hypersensitivity.